Sonova Opens Global Hearing Institute in China

Food and Healthcare Press Releases Tuesday May 9, 2017 08:06
STAEFA, Switzerland--9 May--PRNewswire/InfoQuest

Sonova officially opened its first Audiology Training Center in Suzhou, Jiangsu Province, China. The Sonova Global Hearing Institute is a state of the art training center for current and future hearing care professionals. The Hearing Institute has been established to provide current and future hearing care professionals with the latest theory in hearing rehabilitation practice   and the relevant practical experience to promote best practice in China and the Asia Pacific Region. There is a severe shortage of audiol-ogy experts and hearing care professionals in China and Sonova hopes to improve awareness and enhance the training of clinical practitioners in China. The training facility hosts the latest in Audiological assessment equipment for testing of babies through to adults, as well as the latest innovations in educational technology.

(Photo: http://mma.prnewswire.com/media/509164/Sonova_Hearing_Facility.jpg )
(Photo: http://mma.prnewswire.com/media/509165/Sonova_Leonard_Marshall.jpg )

The center will also be the training ground for the Swiss International Hearing Academy's full hearing care professional course which is a blended learning program consisting of web based learning, face to face workshops, practical sessions and assessments which is expected to start enrolling students in 2018.

Co-operations with local and international government and academic institutions open the center facilities to learners in the wider community and international key opinion leaders in the field of Audiology.

"The establishment of the Sonova Audiology Training Center in China is one of the important strategies for the development of Sonova in the Asia Pacific region and reflects our commitment to China and the Asia Pacific market," Vice President of Sonova Asia Pacific Leonard Marshall said. "Through this initiative we create a state of the art practice space for current and future hearing care professionals, and continue to meet customer needs, create a win - win cooperation model for Asia Pacific, and even for the global hearing care industry".

Sonova AG
Michael Edmond Isaac
Phone: +41-58-928-33-24
E-Mail: mediarelations@sonova.com
Source: Sonova AG

Latest Press Release

Beijing Intellectual Property Court Confirms Judgment Against Wuxi Hisky Medical for Patent Infringement of Technology Used for Echosens# FibroScan(R), Imposes Damages Orders Halt to Manufacturing and Sales

Echosens, an innovative high-technology company offering the FibroScan family of products dedicated to assessment of chronic liver disease, today announces that the Beijing Intellectual Property Court has confirmed judgment against Wuxi Hisky Medical,...

5 Ways to Set Healthy Grocery Shopping Habits in 2019

By Susan Bowerman, M.S., RD, CSSD, CSOWM, FAN, Senior Director, Worldwide Nutrition Education and Training Make your daily staples as healthy as you can. Small changes in the foods you eat every day can add up to big rewards. The holidays are over, and...

Texas Cardiac Arrhythmia Institute at St. David#s Medical Center first in U.S. to treat patient in study to evaluate balloon ablation catheter for treating Atrial Fibrillation

The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently performed the first procedure in the U.S. using the new HELIOSTAR Multi-electrode Radiofrequency (RF) Balloon Ablation Catheter as part of the STELLAR study. The study...

FDA Accepts sBLA and Grants Priority Review for BAVENCIO(R) (avelumab) Plus INLYTA(R) (axitinib) for the Treatment of Advanced Renal Cell Carcinoma

Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for BAVENCIO(R) (avelumab) in combination with INLYTA(R) (axitinib)*...

BioLineRx Announces Closing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has closed its previously announced underwritten public offering of 28,000,000 American Depositary Shares ("ADSs"),...

Related Topics